These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11166888)

  • 1. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.
    Hagiwara Y; Iwasaki T; Asanuma H; Sato Y; Sata T; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(13-14):1652-60. PubMed ID: 11166888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
    Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
    Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant.
    Rask C; Fredriksson M; Lindblad M; Czerkinsky C; Holmgren J
    APMIS; 2000 Mar; 108(3):178-86. PubMed ID: 10752686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K; Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T
    Vaccine; 1994 Sep; 12(12):1083-9. PubMed ID: 7998417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunopotency of the recombinant urease B subunit vaccine of Helicobacter pylori after intranasal administration to mice].
    Gao ZG; Zou QM; Guo G; Guo TS; Zou QM; Zeng WK; Xie QH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):68-70. PubMed ID: 15132912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit.
    de Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
    Vaccine; 1996 Mar; 14(4):260-6. PubMed ID: 8744549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
    Goto N; Maeyama J; Yasuda Y; Isaka M; Matano K; Kozuka S; Taniguchi T; Miura Y; Ohkuma K; Tochikubo K
    Vaccine; 2000 Apr; 18(20):2164-71. PubMed ID: 10715532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.
    Watanabe I; Ross TM; Tamura S; Ichinohe T; Ito S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    Vaccine; 2003 Nov; 21(31):4532-8. PubMed ID: 14575764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].
    Hashigucci K; Tamura S; Kurata T; Kamiya H; Ishidate T
    Kansenshogaku Zasshi; 1997 Feb; 71(2):153-61. PubMed ID: 9077073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).
    Matsuo K; Yoshikawa T; Asanuma H; Iwasaki T; Hagiwara Y; Chen Z; Kadowaki SE; Tsujimoto H; Kurata T; Tamura SI
    Vaccine; 2000 Jun; 18(24):2713-22. PubMed ID: 10781859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulatory sequence oligdeoxynucleotide/cholera toxin B conjugate: a novel allergen-independent intranasal vaccine for allergic rhinitis.
    Won TB; Quan SH; Kim DY; Rhee CS; Lee CH
    Ann Allergy Asthma Immunol; 2009 Apr; 102(4):314-22. PubMed ID: 19441603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.
    Hagiwara Y; Komase K; Chen Z; Matsuo K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 1999 Jul; 17(22):2918-26. PubMed ID: 10438064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ; Weeratna RD; Davis HL
    Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
    Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.
    Komase K; Tamura S; Matsuo K; Watanabe K; Hattori N; Odaka A; Suzuki Y; Kurata T; Aizawa C
    Vaccine; 1998; 16(2-3):248-54. PubMed ID: 9607038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B subunits of cholera toxin and thermolabile enterotoxin of Escherichia coli have similar adjuvant effect as whole molecules on rotavirus 2/6-VLP specific antibody responses and induce a Th17-like response after intrarectal immunization.
    Thiam F; Charpilienne A; Poncet D; Kohli E; Basset C
    Microb Pathog; 2015 Dec; 89():27-34. PubMed ID: 26318874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants.
    Lemere CA; Spooner ET; Leverone JF; Mori C; Clements JD
    Neurobiol Aging; 2002; 23(6):991-1000. PubMed ID: 12470794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).
    Maier M; Seabrook TJ; Lemere CA
    Vaccine; 2005 Oct; 23(44):5149-59. PubMed ID: 16054274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.